Spyre Therapeutics
SYRE
87 hedge funds and large institutions have $352M invested in Spyre Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 13 reducing their positions, and 8 closing their positions.
267% more capital invested
Capital invested by funds: $95.8M → $352M (+$256M)
231% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 13
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
24% more funds holding
Funds holding: 70 → 87 (+17)
0.58% more ownership
Funds ownership: 2.83% → 3.41% (+0.58%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$20.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$20.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.8M |
| 4 |
BlackRock
New York
|
+$9.96M |
| 5 |
O
OrbiMed
New York
|
+$8.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.27M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$534K |
| 3 |
RWM
Ritholtz Wealth Management
New York
|
-$381K |
| 4 |
Renaissance Technologies
New York
|
-$347K |
| 5 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$327K |
SYRE Hedge Fund Activity: Q2 2020 in Review
87 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2020, worth a combined $352M — up 267% from $95.8M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SYRE positions and 8 closed out — a net gain of 17 holders — while 43 added to existing stakes and 13 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $20.6M. The largest seller was Soleus Capital Management, cutting an estimated $1.27M.
- 87 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2020, up from 70 in Q1 2020.
- Funds reported $352M of Spyre Therapeutics stock for Q2 2020, up 267% quarter-over-quarter.
- 25 funds opened new Spyre Therapeutics positions in Q2 2020 and 8 closed out, a net change of +17 holders.
- The largest Spyre Therapeutics buyer in Q2 2020 was Bain Capital Life Sciences Investors, an estimated $20.6M added.
- The largest Spyre Therapeutics seller in Q2 2020 was Soleus Capital Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q2 2020.